GSK · Pharma and healthcare · one day
GSK (GSK): news on Monday 2 November 2026
News from the 24 hours to Monday morning, 2 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centred on an FDA approval for a GSK cancer drug and trial data presented at a major oncology conference, alongside a recap of quarterly financials. The tone is positive for the company's oncology pipeline.
What drove it
- FDA approval
- oncology trial data
- quarterly results
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Tue 27 Oct | +9.3 | 29 |
| Wed 28 Oct | +7.0 | 23 |
| Thu 29 Oct | −6.3 | 77 |
| Fri 30 Oct | −3.7 | 21 |
| Sat 31 Oct | +4.0 | 12 |
| Mon 2 Nov | +8.0 | 3 |
| Tue 3 Nov | +2.7 | 6 |
2 stories · 3 headlines · strongest first
Pharma and healthcare on 2 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK wins FDA approval for Jemperli +8.02 headlines today · Pieces cover FDA clearance for Jemperli and ESMO data on the oncology pipeline. | ||
| +9.7 | Regulatory approval for a cancer drug plus supportive trial data. | |
| +6.3 | Analysis of cancer trial data presented at a major conference, supporting oncology pipeline. | |
| GSK reports third-quarter results, keeps 2026 outlook; shares fall on vaccines −2.51 headline today · 89 in all, since 24 October · A recap covers Q3 financials and the Hibsago approval. | ||
| +7.5 | Recap covers quarterly financials and a regulatory approval for a new GSK product.} ,{ | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.